IL273528B2 - Long-acting conjugates of glp-2 derivatives - Google Patents

Long-acting conjugates of glp-2 derivatives

Info

Publication number
IL273528B2
IL273528B2 IL273528A IL27352820A IL273528B2 IL 273528 B2 IL273528 B2 IL 273528B2 IL 273528 A IL273528 A IL 273528A IL 27352820 A IL27352820 A IL 27352820A IL 273528 B2 IL273528 B2 IL 273528B2
Authority
IL
Israel
Prior art keywords
glp
derivative
lysine
group
region
Prior art date
Application number
IL273528A
Other languages
English (en)
Hebrew (he)
Other versions
IL273528B1 (en
IL273528A (en
Inventor
Sung Youb Jung
In Young Choi
Jaehyuk Choi
Min Young Kim
Original Assignee
Hanmi Pharmaceutical Co Ltd
Sung Youb Jung
In Young Choi
Jaehyuk Choi
Min Young Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Sung Youb Jung, In Young Choi, Jaehyuk Choi, Min Young Kim filed Critical Hanmi Pharmaceutical Co Ltd
Publication of IL273528A publication Critical patent/IL273528A/en
Publication of IL273528B1 publication Critical patent/IL273528B1/en
Publication of IL273528B2 publication Critical patent/IL273528B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL273528A 2017-09-28 2018-09-28 Long-acting conjugates of glp-2 derivatives IL273528B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170126577 2017-09-28
PCT/KR2018/011586 WO2019066586A1 (ko) 2017-09-28 2018-09-28 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체

Publications (3)

Publication Number Publication Date
IL273528A IL273528A (en) 2020-05-31
IL273528B1 IL273528B1 (en) 2025-04-01
IL273528B2 true IL273528B2 (en) 2025-08-01

Family

ID=65902619

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273528A IL273528B2 (en) 2017-09-28 2018-09-28 Long-acting conjugates of glp-2 derivatives

Country Status (18)

Country Link
US (3) US11530249B2 (enExample)
EP (1) EP3689898B1 (enExample)
JP (2) JP7751381B2 (enExample)
KR (2) KR102681143B1 (enExample)
CN (1) CN111433221B (enExample)
AR (1) AR113258A1 (enExample)
AU (1) AU2018339210B2 (enExample)
BR (1) BR112020006189A2 (enExample)
CA (1) CA3084326A1 (enExample)
EA (1) EA202090571A1 (enExample)
IL (1) IL273528B2 (enExample)
MX (1) MX2020004453A (enExample)
PH (1) PH12020550105A1 (enExample)
SA (1) SA520411644B1 (enExample)
SG (1) SG11202002563WA (enExample)
TW (2) TWI795443B (enExample)
WO (1) WO2019066586A1 (enExample)
ZA (1) ZA202001888B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
JP7846622B2 (ja) * 2019-12-24 2026-04-15 ハンミ ファーマシューティカル カンパニー リミテッド Glp-2又はその結合体を含む、代謝性骨疾患の予防又は治療用薬学的組成物
EP4126004A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonist combination
WO2021201654A1 (ko) 2020-04-03 2021-10-07 한미약품 주식회사 Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물
MX2022014671A (es) * 2020-05-22 2023-02-13 Hanmi Pharm Ind Co Ltd Formulacion liquida de conjugado de glp-2 de accion prolongada.
BR112022025141A2 (pt) 2020-06-09 2023-04-25 Vectivbio Ag Fabricação, formulação e dosagem de apraglutida
KR20220092446A (ko) * 2020-12-24 2022-07-01 한미약품 주식회사 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법
JP2025513345A (ja) * 2022-04-18 2025-04-24 ハンミ ファーマシューティカル カンパニー リミテッド 腸疾患の予防又は治療のためのGLP-2と、インスリン分泌ペプチド、TNFα抑制剤、又はその両方の併用療法
CN120435309A (zh) 2022-12-23 2025-08-05 韩美药品株式会社 含有glp-2衍生物或其长效缀合物的用于预防或治疗移植物抗宿主病的药物组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103087A1 (en) * 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
WO2010042145A1 (en) * 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR20110093924A (ko) * 2005-05-04 2011-08-18 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(glp-2) 유사체
KR20120043205A (ko) * 2010-10-26 2012-05-04 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드?2(glp?2)약물 결합체
KR20130078634A (ko) * 2011-12-30 2013-07-10 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
KR20140069131A (ko) * 2011-09-12 2014-06-09 아뮤닉스 오퍼레이팅 인코포레이티드 글루카곤-유사 펩티드-2 조성물 및 이의 제조 및 사용 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103087A1 (en) * 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
KR20110093924A (ko) * 2005-05-04 2011-08-18 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(glp-2) 유사체
WO2010042145A1 (en) * 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR20120043205A (ko) * 2010-10-26 2012-05-04 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드?2(glp?2)약물 결합체
KR20140069131A (ko) * 2011-09-12 2014-06-09 아뮤닉스 오퍼레이팅 인코포레이티드 글루카곤-유사 펩티드-2 조성물 및 이의 제조 및 사용 방법
KR20130078634A (ko) * 2011-12-30 2013-07-10 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체

Also Published As

Publication number Publication date
MX2020004453A (es) 2020-07-24
TW201927806A (zh) 2019-07-16
AU2018339210B2 (en) 2023-02-02
SG11202002563WA (en) 2020-04-29
CA3084326A1 (en) 2019-04-04
SA520411644B1 (ar) 2024-02-25
JP2023138505A (ja) 2023-10-02
AR113258A1 (es) 2020-03-11
CN111433221A (zh) 2020-07-17
JP7751381B2 (ja) 2025-10-08
EP3689898A4 (en) 2021-06-16
EP3689898B1 (en) 2026-04-29
CN111433221B (zh) 2024-12-27
BR112020006189A2 (pt) 2020-10-13
JP2020534840A (ja) 2020-12-03
TWI794897B (zh) 2023-03-01
US20230090790A1 (en) 2023-03-23
IL273528B1 (en) 2025-04-01
US20200262888A1 (en) 2020-08-20
WO2019066586A1 (ko) 2019-04-04
KR20240013836A (ko) 2024-01-30
IL273528A (en) 2020-05-31
KR102681143B1 (ko) 2024-07-04
TW202142560A (zh) 2021-11-16
TWI795443B (zh) 2023-03-11
KR20190037181A (ko) 2019-04-05
US20220251164A1 (en) 2022-08-11
NZ762962A (en) 2024-07-05
ZA202001888B (en) 2021-05-26
KR102681144B1 (ko) 2024-07-04
EA202090571A1 (ru) 2020-07-30
PH12020550105A1 (en) 2020-12-07
AU2018339210A1 (en) 2020-04-16
EP3689898A1 (en) 2020-08-05
US11530249B2 (en) 2022-12-20

Similar Documents

Publication Publication Date Title
IL273528B2 (en) Long-acting conjugates of glp-2 derivatives
JP2020534840A5 (enExample)
Fathi et al. Elastin based cell-laden injectable hydrogels with tunable gelation, mechanical and biodegradation properties
Luo et al. Biodegradable multiblock poly [N-(2-hydroxypropyl) methacrylamide] via reversible addition− fragmentation chain transfer polymerization and click chemistry
Geng et al. Site-directed conjugation of “clicked” glycopolymers to form glycoprotein mimics: binding to mammalian lectin and induction of immunological function
KR101770844B1 (ko) 폴리에틸렌 글리콜 기반의 생분해성 수불용성 하이드로겔
You et al. Synthesis of temperature-responsive heterobifunctional block copolymers of poly (ethylene glycol) and poly (N-isopropylacrylamide)
JP4824404B2 (ja) 脂肪族生物分解性リンカーに基づく放出可能なポリマー複合体
JP2021516960A5 (enExample)
US20010044526A1 (en) N-maleimidyl polymer derivatives
NZ630888A (en) Antibody drug conjugate (adc) purification
JP2015503554A5 (enExample)
MXPA03005460A (es) Sintesis de derivados polimericos no peptidicos de peso molecular alto.
GB2529356A (en) Novel linker and preparation method thereof
CA2558583C (en) Polymer-based compositions and conjugates of hiv entry inhibitors
Steinbach et al. Reversible bioconjugation: biodegradable poly (phosphate)‐protein conjugates
KR20210119450A (ko) 항체-약물 컨쥬게이트용 글리코시드-함유 펩타이드 링커
WO2007062610A3 (es) Dendrímero con peg de cuatro ramas para la conjugación a proteínas y péptidos
KR20170071485A (ko) Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법
Williams et al. RAFT‐Derived Polymer–Drug Conjugates: Poly (hydroxypropyl methacrylamide)(HPMA)–7‐Ethyl‐10‐hydroxycamptothecin (SN‐38) Conjugates
Hakimi et al. Thiolated methylated dimethylaminobenzyl chitosan: A novel chitosan derivative as a potential delivery vehicle
Andersson et al. Poly (ethylene glycol)-poly (ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates
Monaco et al. Multi-arm star-shaped glycopolymers with precisely controlled core size and arm length
WO2024148827A1 (zh) 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物
Joshi et al. Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid